Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2006-12-4
pubmed:abstractText
Prion disease refers to a group of fatal transmissible neurodegenerative diseases for which no pharmacological treatment is available. The cellular prion protein (PrP(C)) is required for both prion replication and pathogenesis, and reducing PrP(C) levels has been shown to extend survival time after prion infection. RNA interference (RNAi) is a sequence-specific posttranscriptional gene silencing mechanism. In this issue of the JCI, Pfeifer et al. report that lentivector-mediated RNAi significantly reduced neuronal PrP(C) expression; effectively suppressed accumulation of the infectious protease-resistant form of PrP (PrP(Sc)) in a persistently infected neuroblastoma cell line; and markedly slowed the progression of prion disease in a unique chimeric mouse model (see the related article beginning on page 3204). These findings indicate that lentivector-mediated RNAi could, in principle, be developed for the therapy of prion disease.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-11584312, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-15113880, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-15235598, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-15768029, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-15811941, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16136043, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16259557, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16816104, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16816391, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16909029, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16927374, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16929313, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16929317, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16940756, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-16981681, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-17005675, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-17143329, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-7912659, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-8552188, http://linkedlifedata.com/resource/pubmed/commentcorrection/17143323-9811807
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3101-3
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
RNAi: a novel strategy for the treatment of prion diseases.
pubmed:affiliation
Department of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA. qxk2@case.edu
pubmed:publicationType
Journal Article, Comment